ATE546136T1 - Kardioprotektions- und neuroprotektionsverfahren durch intravenöse verabreichung von halogenierten flüchtigen narkosemitteln - Google Patents
Kardioprotektions- und neuroprotektionsverfahren durch intravenöse verabreichung von halogenierten flüchtigen narkosemittelnInfo
- Publication number
- ATE546136T1 ATE546136T1 AT03774657T AT03774657T ATE546136T1 AT E546136 T1 ATE546136 T1 AT E546136T1 AT 03774657 T AT03774657 T AT 03774657T AT 03774657 T AT03774657 T AT 03774657T AT E546136 T1 ATE546136 T1 AT E546136T1
- Authority
- AT
- Austria
- Prior art keywords
- cardioprotection
- neuroprotection
- procedures
- intravenous administration
- volatile anesthetic
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000003983 inhalation anesthetic agent Substances 0.000 title abstract 2
- 230000005961 cardioprotection Effects 0.000 title 1
- 238000001990 intravenous administration Methods 0.000 title 1
- 230000004112 neuroprotection Effects 0.000 title 1
- 230000000302 ischemic effect Effects 0.000 abstract 4
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 230000002107 myocardial effect Effects 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41793402P | 2002-10-11 | 2002-10-11 | |
| PCT/US2003/031826 WO2004032858A2 (en) | 2002-10-11 | 2003-10-09 | Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE546136T1 true ATE546136T1 (de) | 2012-03-15 |
Family
ID=32094122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03774657T ATE546136T1 (de) | 2002-10-11 | 2003-10-09 | Kardioprotektions- und neuroprotektionsverfahren durch intravenöse verabreichung von halogenierten flüchtigen narkosemitteln |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7999011B2 (de) |
| EP (1) | EP1558226B1 (de) |
| JP (1) | JP5210486B2 (de) |
| KR (2) | KR101403264B1 (de) |
| CN (2) | CN102283821A (de) |
| AT (1) | ATE546136T1 (de) |
| AU (1) | AU2003282464B2 (de) |
| BR (1) | BR0314617A (de) |
| CA (1) | CA2500310C (de) |
| DK (1) | DK1558226T3 (de) |
| ES (1) | ES2382911T3 (de) |
| HK (1) | HK1079703A1 (de) |
| IL (1) | IL167472A (de) |
| MX (1) | MXPA05003741A (de) |
| NZ (1) | NZ539298A (de) |
| PL (1) | PL219493B1 (de) |
| RU (1) | RU2350323C2 (de) |
| WO (1) | WO2004032858A2 (de) |
| ZA (1) | ZA200502741B (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1558755A (zh) | 2001-09-26 | 2004-12-29 | ���ع��ʹ�˾ | 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒 |
| CA2511598C (en) | 2002-12-24 | 2016-09-13 | Rinat Neuroscience Corp. | Anti-ngf antibodies and methods using same |
| JP2010504359A (ja) | 2006-09-20 | 2010-02-12 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 局部麻酔および／または疼痛緩和のための、揮発性麻酔剤を送達するための方法 |
| GB0619499D0 (en) | 2006-10-03 | 2006-11-08 | Lucent Technologies Inc | Encrypted data in a wireless telecommunications system |
| DE112008002914A5 (de) * | 2007-11-06 | 2010-09-30 | B. Braun Melsungen Ag | Einen hydrophoben Wirkstoff enthaltende wässrige Emulsionen |
| AU2009206390B2 (en) * | 2008-01-22 | 2014-10-30 | The Board Of Regents Of The University Of Texas System | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |
| AU2015200210B2 (en) * | 2008-01-22 | 2016-08-11 | The Board Of Regents Of The University Of Texas System | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |
| JP5835542B2 (ja) * | 2008-01-22 | 2015-12-24 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 揮発性麻酔薬組成物およびその使用 |
| CN102458557B (zh) * | 2009-05-05 | 2018-11-27 | 德州大学系统董事会 | 挥发性麻醉剂的新型制剂及其用于减轻炎症的使用方法 |
| RU2408396C1 (ru) * | 2009-07-30 | 2011-01-10 | Государственное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия Федерального агентства по здравоохранению и федеральному развитию" | Комбинированная двухсегментарная регионарная анестезия при выполнении каротидной эндартерэктомии у больных критической ишемией нижних конечностей и выраженным болевым синдромом |
| EP2459182B1 (de) | 2009-07-30 | 2017-09-06 | University of Zürich | Injizierbare formulierung für behandlung und schutz von patienten mit einer entzündungsreaktion oder einem ischämie-reperfusionsereignis |
| FR2956323B1 (fr) * | 2010-02-15 | 2013-12-20 | Air Liquide | Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques |
| AU2012272933B2 (en) * | 2011-06-24 | 2016-08-11 | Vapogenix, Inc. | Novel formulations and methods for treating dermatological disorders or diseases |
| CA2906072C (en) | 2013-03-15 | 2023-01-10 | Vapogenix, Inc. | Analgesic compositions comprising halogenated volatile compounds |
| ITMO20130075A1 (it) * | 2013-03-22 | 2014-09-23 | Enrico Giuliani | Dispositivo di somministrazione |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1018773A (en) * | 1962-09-13 | 1966-02-02 | Bellon Labor Sa Roger | ª‡-phenyl-ª‰-2-furyl-propionitrile derivatives |
| US4073943A (en) | 1974-09-11 | 1978-02-14 | Apoteksvarucentralen Vitrum Ab | Method of enhancing the administration of pharmalogically active agents |
| US5628930A (en) | 1992-10-27 | 1997-05-13 | Alliance Pharmaceutical Corp. | Stabilization of fluorocarbon emulsions |
| US5635538A (en) | 1993-03-16 | 1997-06-03 | Alliance Pharmaceutical Corp. | Fluorocarbon emulsions with reduced pulmonary gas-trapping properties |
| JP2961034B2 (ja) * | 1993-09-16 | 1999-10-12 | アルプス電気株式会社 | 磁気ヘッド |
| EP0720605B1 (de) | 1993-09-24 | 2001-12-19 | University Of British Columbia | Aminocyclohexylester und ihre anwendung |
| FR2726267B1 (fr) * | 1994-10-26 | 1998-01-02 | Smithkline Beecham Lab | Nouveaux agents anti-arythmiques, compositions pharmaceutiques les contenant, et procede pour les preparer |
| GB2350297A (en) * | 1999-05-27 | 2000-11-29 | Abbott Lab | Injectable halogenated anesthetic formulation in emulsion form |
| AU2001280778B2 (en) * | 2000-07-26 | 2004-09-02 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
-
2003
- 2003-10-09 AT AT03774657T patent/ATE546136T1/de active
- 2003-10-09 NZ NZ539298A patent/NZ539298A/en not_active IP Right Cessation
- 2003-10-09 DK DK03774657.5T patent/DK1558226T3/da active
- 2003-10-09 AU AU2003282464A patent/AU2003282464B2/en not_active Ceased
- 2003-10-09 CN CN2011101820964A patent/CN102283821A/zh active Pending
- 2003-10-09 ES ES03774657T patent/ES2382911T3/es not_active Expired - Lifetime
- 2003-10-09 BR BR0314617-0A patent/BR0314617A/pt not_active Application Discontinuation
- 2003-10-09 PL PL376217A patent/PL219493B1/pl unknown
- 2003-10-09 JP JP2004543499A patent/JP5210486B2/ja not_active Expired - Lifetime
- 2003-10-09 CA CA2500310A patent/CA2500310C/en not_active Expired - Fee Related
- 2003-10-09 HK HK05112083.8A patent/HK1079703A1/zh unknown
- 2003-10-09 US US10/682,303 patent/US7999011B2/en active Active
- 2003-10-09 CN CNA2003801012256A patent/CN1703209A/zh active Pending
- 2003-10-09 EP EP03774657A patent/EP1558226B1/de not_active Expired - Lifetime
- 2003-10-09 MX MXPA05003741A patent/MXPA05003741A/es active IP Right Grant
- 2003-10-09 KR KR1020057006049A patent/KR101403264B1/ko not_active Expired - Fee Related
- 2003-10-09 WO PCT/US2003/031826 patent/WO2004032858A2/en not_active Ceased
- 2003-10-09 RU RU2005114008/14A patent/RU2350323C2/ru not_active IP Right Cessation
- 2003-10-09 KR KR1020127005009A patent/KR20120030598A/ko not_active Ceased
-
2005
- 2005-03-16 IL IL167472A patent/IL167472A/en active IP Right Grant
- 2005-04-05 ZA ZA200502741A patent/ZA200502741B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL376217A1 (en) | 2005-12-27 |
| ZA200502741B (en) | 2006-02-22 |
| EP1558226B1 (de) | 2012-02-22 |
| KR101403264B1 (ko) | 2014-06-02 |
| CN102283821A (zh) | 2011-12-21 |
| KR20050056230A (ko) | 2005-06-14 |
| HK1079703A1 (zh) | 2006-04-13 |
| CA2500310A1 (en) | 2004-04-22 |
| PL219493B1 (pl) | 2015-05-29 |
| EP1558226A4 (de) | 2008-04-02 |
| US20040127578A1 (en) | 2004-07-01 |
| KR20120030598A (ko) | 2012-03-28 |
| US7999011B2 (en) | 2011-08-16 |
| IL167472A (en) | 2013-10-31 |
| MXPA05003741A (es) | 2005-06-17 |
| EP1558226A2 (de) | 2005-08-03 |
| NZ539298A (en) | 2008-11-28 |
| WO2004032858A3 (en) | 2004-09-23 |
| BR0314617A (pt) | 2005-08-02 |
| JP5210486B2 (ja) | 2013-06-12 |
| DK1558226T3 (da) | 2012-05-07 |
| CN1703209A (zh) | 2005-11-30 |
| RU2350323C2 (ru) | 2009-03-27 |
| WO2004032858A2 (en) | 2004-04-22 |
| CA2500310C (en) | 2013-03-12 |
| AU2003282464B2 (en) | 2010-02-25 |
| AU2003282464A1 (en) | 2004-05-04 |
| ES2382911T3 (es) | 2012-06-14 |
| JP2006504740A (ja) | 2006-02-09 |
| RU2005114008A (ru) | 2005-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE546136T1 (de) | Kardioprotektions- und neuroprotektionsverfahren durch intravenöse verabreichung von halogenierten flüchtigen narkosemitteln | |
| JP2006501240A5 (de) | ||
| BRPI0406667A (pt) | Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg | |
| BR9911076A (pt) | Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica | |
| ES2224430T3 (es) | Noribogaina en el tratamiento del dolor y de la toxicomania. | |
| Meechan et al. | The use of patient-controlled transcutaneous electronic nerve stimulation (TENS) to decrease the discomfort of regional anaesthesia in dentistry: A randomised controlled clinical trial | |
| BR0315573A (pt) | Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica | |
| Jayakaran et al. | Local anesthetics in pediatric dental practice | |
| Gupta et al. | “Sodium bicarbonate”: an adjunct to painless palatal anesthesia | |
| Kulkarni et al. | Painless anaesthesia in pediatric dentistry: an updated review | |
| BRPI0409699A (pt) | métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos | |
| Barker et al. | Femoral nerve blockade administered preclinically for pain relief in severe knee trauma is more feasible and effective than intravenous metamizole: a randomized controlled trial | |
| KR900701309A (ko) | 액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법 | |
| WO2001080895A3 (en) | Methods and compositions for the treatment of cardiac indications | |
| Buhse | Efficacy of EMLA cream to reduce fear and pain associated with interferon beta-1a injection in patients with multiple sclerosis | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| UA27230C2 (uk) | Похідні андростану, заміщені по 16-му положенню четвертинною амонієвою групою, для використання як нервово-м'язових блокаторів та фармацевтична композиція, що здатна викликати нервово-м'язову блокаду | |
| ATE446309T1 (de) | Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung | |
| Neill | Postoperative analgesia following brachial plexus block | |
| AU2012244095A1 (en) | Method for the non-surgical treatment of lipodystrophy in a retrovirus-infected individual | |
| Padmanabhan et al. | Dental Anesthesia: Can Needle-Free Injections Help | |
| EA200600757A1 (ru) | Тетрапептид, регулирующий уровень глюкозы в крови при сахарном диабете | |
| RU2177303C2 (ru) | Способ лечения ортопедических больных периартикулярным введением препарата | |
| Yaacob et al. | The efficacy of xylocaine topical anaesthetic in reducing injection pain | |
| COŞAR et al. | Pain control following lumbar laminectomy: Comparison of epidural morphine and morphine plus bupivacaine |